Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer

Yu Tong; Zhai XiaoFeng; Liu Qun; Meng YongBin; Lu JianYing; Chen Zhe

doi:10.3969/j.issn.1001-5256.2017.02.015

Issue 2

Feb. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(2): 281-285

PDF( 1640 KB)

Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2017.02.015

Shanghai University of Traditional Chinese Medicine

Research funding:

Received Date: 2016-10-08
Published Date: 2017-02-20

Abstract

Abstract

Objective To investigate the clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization( TACE) in the treatment of Barcelona Clinic Liver Cancer( BCLC) stage C primary liver cancer.Methods A retrospective analysis was performed for the clinical data of 82 patients with BCLC stage C primary liver cancer who were admitted to Department of TCM Oncology in Changhai Hospital from December 2010 to October 2014.According to intraoperative medication,the patients were divided into two groups.The 40 patients in the cinobufotalin group were treated with hepatic arterial infusion with cinobufotalin combined with lipiodol embolism,and the 42 patients in the control group underwent TACE with epirubicin.The objective response rate,time to progression,median survival time,and acute adverse events were compared between the two groups after a single treatment.The t- test was used for comparison of continuous data between groups,the chi- square test was used for comparison of categorical data between groups,and the Kaplan- Meier method was used for the analysis of cumulative survival rate.Results At 1.5 months after surgery,the cinobufotalin group had a significantly higher objective response rate than the control group( 27.5% vs 9.52%,χ~2= 4.429,P = 0.035).The time to progression was 2.4 months( 95% CI:1.978- 2.822) in the cinobufotalin group and 3.0 months( 95% CI:2.260- 3.740) in the control group,and there was no significant difference between the two groups( P = 0.344).The median survival time was 6.6 months( 95% CI:4.131-9.069) in the cinobufotalin group and 10.3 months( 95% CI:0.089- 20.511) in the control group,and there was no significant difference between the two groups( P = 0.132).At 5 days after surgery,the cinobufotalin group had significantly lower incidence rates of abnormal alanine aminotransferase level,white blood cell count,and platelet count,as well as adverse events including hepatalgia,abdominal distension,and nausea / vomiting than the control group( χ~2= 6.193,5.311,6.096,5.909,4.761,and 4.173,all P < 0.05).Conclusion As for patients with BCLC stage C primary liver cancer,hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization has a better short- term therapeutic effect,milder adverse effects,and a similar long- term therapeutic effect compared with TACE with conventional chemotherapeutic agents.
- liver neoplasms,
- chemotherapy,
- cancer,
- regional perfusion,
- chemoembolization

FullText(HTML)

References(24)

References

[1]TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.

[2]LLOVET JM,BURROUGHS A,BRUIX J.Hepatocellular carcinoma[J].Lancet,2003,362(9399):1907-1917.

[3]LLOVET JM,BRU C,BRUIX J.Prognosis of hepatocellular carcinoma:the BCLC staging classification[J].Semin Liver Dis,1999,19(3):329-338.

[4]CHUNG GE,LEE JH,KIM HY,et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J].Radiology,2011,258(2):627-634.

[5]SATORU M,TAKAHIKO M,FUMIE S,et al.Interventional treatment for unresectable hepatocellular carcinoma[J].World J Gastroenterology,2014,20(37):13453-13465.

[6]BRUIX J,LLOVET JM,CASTELLS A,et al.Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma:results of a randomized,controlled trial in a single institution[J].Hepatology,1998,27(6):1578-1583.

[7]LIU Y,LI GY,ZHAO XX,et al.Research advances in traditional Chinese medicine combined with interventional therapy for hepatocellular carcinoma[J].J Clin Hepatol,2015,31(1):118-122.(in Chinese)刘洋,李桂英,赵相轩,等.中药结合介入手段治疗肝癌的研究进展[J].临床肝胆病杂志,2015,31(1):118-122.

[8]CAO YJ,YANG JK,YANG JZ.Research advance in treatment of primary liver cancer with Cinobufacini injection[J].Shanghai JTradit Chin Med,2012,46(4):86-88.(in Chinese)曹亚娟,杨金坤,杨金祖.华蟾素注射液治疗原发性肝癌研究进展[J].上海中医药杂志,2012,46(4):86-88.

[9]WANG LL,ZHANG YH,CHEN XY.AASLD Practice guideline:management of hepatocelluar carcinoma[J].Beijing Med J,2011,33(3):236-251.(in Chinese)王莉琳,张永宏,陈新月.2010年美国肝病年会(AASLD)肝细胞癌诊疗指南[J].北京医学,2011,33(3):236-251.

[10]LENCIONI R,LLOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.

[11]HAN K,KIM JH.Transarterial chemoembolization in hepatocellular carcinoma treatment:Barcelona clinic liver cancer staging system[J].World J Gastroenterology,2015,21(36):10327-10335.

[12]CHO JY,PAIK YH,PARK HC,et al.The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma[J].Liver Int,2014,34(5):795-801.

[13]IZUMI R,SHIMIZU K,MIYAZAKI I.Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma[J].Hepatogastroenterology,1996,43(12):1415-1420.

[14]SHIM JH,PARK JW,KIM JH,et al.Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients[J].Cancer Science,2008,99(10):2037-2044.

[15]RANIERI G,AMMENDOLA M,MARECH I,et al.Vascular endothelial growth factor and tryptase changes after chemoembolization in hepatocarcinoma patients[J].World J Gastroenterol,2015,21(19):6018-6025.

[16]KAWAI S,OKAMURA J,OGAWA M,et al.Prospective and randomized clinical trial for the treatment of hepatocellular carcinomaa comparison of lipiodol-transcatheter arterial embolizaion with and without adriamycin(first cooperative study)[J].Cancer Chemother Pharmacol,1992,31(Suppl):s1-s6.

[17]MALAGARI K,POMONI M,KELEKIS A,et al.Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead Block for hepatocellular carcinoma[J].Cardiovasc Intervent Radiol,2010,33(3):541-551.

[18]WANG SS,LI B,ZHAI XF.Research advances in antitumor effect of cinobufotalin injection and related mechanism[J].J Shandong Univ Tradit Chin Med,2008,32(5):436-438.(in Chinese)王双双,李柏,翟笑枫.华蟾素注射液抗肿瘤应用及其机制研究进展[J].山东中医药大学学报,2008,32(5):436-438.

[19]JI JF,DENG XL,XIAO QJ,et al.Percutaneous cinobufotalin injection under ultrasonography combined with transcatheter arterial chemoembolization on treating portal vein tumor thrombus[J].JChangchun Univ Chin Med,2015,31(5):1059-1062.(in Chinese)冀建峰,邓晓莉,肖秋金,等.超声介入华蟾素联合肝动脉化疗栓塞治疗门静脉癌栓[J].长春中医药大学学报,2015,31(5):1059-1062.

[20]LI Q,SUN BM,PENG YH,et al.Clinical study on the treatment of primary liver cancer by cinobufotain combined with transcatheter arterial chemoembolization[J].Acta Univ Tradit Med Sin Pharmacol Shanghai,2008,22(2):32-34.(in Chinese)李琦,孙保木,彭永海,等.华蟾素联合肝动脉介入化疗栓塞治疗原发性肝癌的临床研究[J].上海中医药大学学报,2008,22(2):32-34.

[21]DONG HJ,ZHANG LJ,ZHAI XF,et al.Effects of different nursing methods in treatment of phlebitis caused by cinobufacini injection[J].J Chin Integr Med,2007,5(5):585-587.(in Chinese)董惠娟,张玲娟,翟笑枫,等.不同护理方法防治华蟾素所致静脉炎的效果观察[J].中西医结合学报,2007,5(5):585-587.

[22]HANKS BA,SUHOCKI PV,DELONG DM,et al.The efficacy and tolerability of transarterial chemo-embolization(TACE)compared with transarterial embolization(TAE)for patients with unresectable hepatocellular carcinoma(HCC)[J].J Clin Oncol,2008,26(15):4595.

[23]ZHOU LH,HOU YM,LI XF.Adverse effects of cinobufotalin injection and related nursing strategies[J].J Guangxi Med Univ,2016,33(2):375-376.(in Chinese)周柳红,候毅梅,黎绣芬.华蟾素注射液治疗中出现的不良反应及护理对策[J].广西医科大学学报,2016,33(2):375-376.

[24]SHEN JJ.Clinical effect of interventional embolization combined with intravenous injection of cinobufotalin in treatment of primary liver cancer[J].J Clin Hepatol,2009,25(3):207-209.(in Chinese)沈建军.华蟾素介入栓塞联合静脉注射对原发性肝癌的临床疗效[J].临床肝胆病杂志,2009,25(3):207-209.

Relative Articles

[1]	WANG WenHui, DUAN XuHua, LI Hao, LI FengYao, JU ShuGuang, WANG ManZhou, REN JianZhuang, HAN XinWei. Effect of arsenic trioxide-loaded CalliSpheres beads in the treatment of rabbits with VX2 liver tumor[J]. Journal of Clinical Hepatology, 2020, 36(12): 2730-2734. doi: 10.3969/j.issn.1001-5256.2020.12.018
[2]	Sun DongXue, Yang Zhu, Long FengXi, Wei XianMan, Tang DongXin. Efficacy and safety of Kanglaite injection combined with transarterial chemoembolization in treatment of advanced liver cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 363-368. doi: 10.3969/j.issn.1001-5256.2020.02.026
[3]	Sun Yu, Zhang HongHai, Sheng ShouPeng, Li Cong, Yuan ChunWang, Cui ShiChang, Hu CaiXia, Liu BoJun, Li XingMing, Zhang YongHong, Zheng JiaSheng. Clinical effect of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of Barcelona Clinical Liver Cancer stage B primary liver cancer and influencing factors for prognosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 818-824. doi: 10.3969/j.issn.1001-5256.2019.04.022
[4]	Yin WeiLi, Lian Jia, Xiao ShiXiang, Xiang HuiLing, Liu Ying, Qian BaoXin, Wang Tao, Li Ying, Jin YuXia, Han Tao. Clinical effect of drug-eluting beads and conventional transcatheter arterial chemoembolization in treatment of unresectable liver cancer: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1270-1275. doi: 10.3969/j.issn.1001-5256.2019.06.018
[5]	Xing AiLi, Zheng JiaSheng. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. Journal of Clinical Hepatology, 2019, 35(1): 98-103. doi: 10.3969/j.issn.1001-5256.2019.01.018
[6]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[7]	Wang ChunMei, Ceng JianTing, Luo XianZhang, Liu Ya. Clinical effect of S-1 in treatment of circulating tumor cell-positive patients after radical surgery for primary hepatic carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(3): 513-516. doi: 10.3969/j.issn.1001-5256.2018.03.012
[8]	Wang QiaoYu, Pan Jie, Zhou YuanMin. Clinical effect of transarterial chemoembolization combined with endovascular implantation of iodine-125 seeds in treatment of primary liver cancer complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2018, 34(1): 137-141. doi: 10.3969/j.issn.1001-5256.2018.01.028
[9]	Li Hao, Duan XuHua, Han XinWei, Ren JianZhuang, Li FengYao, Kuang DongLin, Li FangZheng. Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in treatment of rabbit VX2 liver tumors[J]. Journal of Clinical Hepatology, 2018, 34(4): 779-783. doi: 10.3969/j.issn.1001-5256.2018.04.017
[10]	Li Xin. Short-and long-term efficacy of transarterial chemoembolization versus liver resection in treatment of patients with Barcelona stage B multiple hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1296-1300. doi: 10.3969/j.issn.1001-5256.2017.07.018
[11]	An DongJun, An Lin, Zhang Cheng, Zhao WeiAn, Han Li. Efficacy of laparoscopic microwave ablation in treatment of malignant liver tumors[J]. Journal of Clinical Hepatology, 2017, 33(11): 2158-2161. doi: 10.3969/j.issn.1001-5256.2017.11.021
[12]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[13]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[14]	Hao MingZhi, Lin HaiLan, Chen QiZhong, Hu YuBin. Effect of recombinant human endostatin combined with hepatic artery interventional therapy on progression-free survival of patients with advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 92-96. doi: 10.3969/j.issn.1001-5256.2016.01.016
[15]	Hu CaiXia, Zheng JiaSheng, Cui ShiChang, Qian ZhiLing. Efficacy of nutritional intervention in patients with primary hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J]. Journal of Clinical Hepatology, 2015, 31(4): 569-572. doi: 10.3969/j.issn.1001-5256.2015.04.022
[16]	Liu Qi, Wu ZhenMing, Qi XiuHeng, Guo Qian. Survival analysis of intrahepatic arterial infusion of Endostar combined with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 225-227. doi: 10.3969/j.issn.1001-5256.2015.02.019
[17]	Ye ShengLong. Loco-regional therapy for liver cancer[J]. Journal of Clinical Hepatology, 2013, 29(1): 28-31.
[18]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[19]	Guan Tie, Zou QingHua. The clinical observation of continuous hyperthermic peritoneal perfusion chemotherapy with endogenetic field tumor hyperthemic system in the treatment of advanced primary hepatic carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(5): 531-532+544.
[20]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(9)

1.	杨悦，续嗣钰，王珏，杜施霖，张春蕾，宋海燕. 华蟾素调控AKT介导的上皮间质转化抑制肝细胞癌肺转移裸鼠模型的作用机制. 临床肝胆病杂志. 2024(09): 1840-1847 . 本站查看
2.	赵河通，翟笑枫. 经肝动脉中药栓塞术在原发性肝癌治疗中的创新应用. 中医肿瘤学杂志. 2023(06): 80-86 .
3.	田智萍，王开云，张鑫，杨付珍，周云萍，徐城林. 动脉置管灌注中药华蟾素注射液对TACE术后原发性肝癌患者HIF-1α、VEGF的影响及其机理探讨. 现代消化及介入诊疗. 2022(03): 358-362 .
4.	张伟. 华蟾素对TACE术治疗肝细胞肝癌后肝内复发和血清VEGF/TSGF表达的影响. 辽宁中医杂志. 2022(12): 72-75 .
5.	李岳勇，韦忠恒，钟秋红，吴英宁，姜秋兰，周石，汪建初. 中药华蟾素对肝细胞肝癌TACE术后肝内复发和血清VEGF/TSGF表达的影响. 辽宁中医杂志. 2020(01): 131-134 .
6.	洪桂花，陈思环，黄珊. 复方斑蝥胶囊对原发性肝癌患者免疫功能及临床疗效的影响. 世界中西医结合杂志. 2020(02): 365-368+373 .
7.	夏念信，邱宝安，刘鹏，祝建勇，赵文超，安阳. 奥施康定联合复方苦参注射液治疗肝癌晚期癌痛疗效观察. 临床军医杂志. 2018(07): 735-736+740 .
8.	姜海英. 中西医结合治疗原发性肝癌的效果分析. 中国医药指南. 2018(27): 178-179 .
9.	于童，陈喆. 华蟾素注射液治疗中晚期肝癌临床研究进展. 中西医结合肝病杂志. 2017(05): 319-321 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1736) PDF downloads(404)

Clinical effect and safety of hepatic arterial infusion of cinobufotalin injection combined with lipiodol chemoembolization in treatment of Barcelona Clinic Liver Cancer stage C primary liver cancer

DOI: 10.3969/j.issn.1001-5256.2017.02.015